期刊文献+

清肺化痰汤加减对老年晚期非小细胞肺癌(痰热郁肺证)的辅助化疗效果 被引量:1

Adjuvant Chemotherapy Effects of Qingfei Huatan Decoction in Elderly Patients with Advanced Non-small Cell Lung Cancer(Phlegm Heat Obstructing Lung Syndrome)
下载PDF
导出
摘要 目的:观察清肺化痰汤加减对老年晚期非小细胞肺癌(NSCLC)(痰热郁肺证)的辅助化疗效果。方法:老年晚期NSCLC患者80例随机分为对照组和观察组各40例。对照组采用多西他赛联合顺铂(DP)方案化疗,观察组在对照组基础上加用清肺化痰汤加减。治疗4个疗程后,比较两组患者治疗前后的中医证候积分、生存质量(FACT-L),以及癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和细胞角质素片段抗原(CYRAF21-1)等血清肿瘤标记物水平变化;评价临床疗效(总缓解率、临床获益率),统计两组不良反应发生情况。结果:治疗后,两组患者中医症候积分、血清肿瘤标记物水平均较治疗前明显降低,FACT-L评分则较前明显提高(P<0.05);且观察组上述指标均明显优于对照组(P<0.05)。观察组总缓解率和临床获益率均明显高于对照组(P<0.05)。观察组恶心呕吐发生率明显低于对照组(P<0.05),血红蛋白降低、白细胞减少、肝功能损伤发生率两组差异无统计学意义(P>0.05)。结论:清肺化痰汤加减可有助于降低老年晚期NSCLC(痰热郁肺证)临床症状,降低肿瘤标志物水平和药物不良反应发生率,提高生存质量,效果显著。 Objective:To study the adjuvant chemotherapy effects of Qingfei Huatan decoction in elderly patients with advanced non-small cell lung cancer(NSCLC)(phlegm heat stagnant lung syndrome).Methods:A total of 80 elderly patients with advanced NSCLC were randomly divided into control group and observation group with 40 cases in each group.The control group was treated with DP chemotherapy,and the observation group was additionally treated with Qingfei Huatan decoction on the basis of the control group.After 4 courses of treatment,the TCM syndrome scores,functional assessment of cancer therapy-lung(FACT-L),levels of serum tumor markers of carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and cytokeratin fragment antigen(CYRAF21-1)between the two groups were compared and analyzed before and after treatment.The clinical efficacy after treatment(total remission rate,clinical benefit rate)were compared to evaluate the efficacy,and the occurrence of adverse reactions between the two groups were recorded.Results:After treatment,the TCM symptom scores and serum tumor marker levels of the two groups were all lower than those before treatment,and the FACT-L scores were significantly higher than those before treatment(P<0.05);the above indicators of the observation group were significantly better than those of the control group(P<0.05).After treatment,the total remission rate and clinical benefit rate of the observation group were significantly higher than those of the control group(P<0.05).During the treatment,the incidence of nausea and vomiting of the observation group was significantly lower than that of the control group(P<0.05),there were no significant differences between the two groups in the incidences of hemoglobin reduction,leukopenia and liver function damage(P>0.05).Conclusion:Qingfei Huatan decoction can help reduce the clinical symptoms of elderly patients with advanced NSCLC(phlegm-heat stagnant lung syndrome),reduce the levels of tumor markers and the incidence of adverse reactions of chemotherapy drugs,and improve the quality of life with remarkable curative effect.
作者 尹枭孟 吴君华 郭建英 冯勇 徐维国 Yin Xiaomeng;Wu Junhua;Guo Jianying;Feng Yong;Xu Weiguo(Department of Respiratory and Critical Care Medicine,Mianyang Central Hospital,Sichuan Mianyang 621000,China)
出处 《中国药师》 CAS 2022年第8期1390-1393,1435,共5页 China Pharmacist
基金 四川省医学会专项科研课题(编号:2019HR59) 中国宋庆龄基金会项目(编号:2018MZFS-046)。
关键词 晚期非小细胞肺癌 老年患者 痰热郁肺证 清肺化痰汤加减 肿瘤标志物 辅助疗效 Advanced non-small cell lung cancer Elderly patients Phlegm heat obstructing lung syndrome Qingfei Huatan decoction Tumor markers Adjuvant therapy
  • 相关文献

参考文献15

二级参考文献176

  • 1高雅婷,吴迪,李泽庚,童佳兵,张星星,杨勤军.中西医结合干预疗法对肺癌患者生活质量影响的Meta分析[J].世界科学技术-中医药现代化,2020,22(7):2246-2255. 被引量:6
  • 2张连文,袁世宏.隐结构模型与中医辨证研究(Ⅰ)——隐结构法的基本思想及隐结构分析工具[J].北京中医药大学学报,2006,29(6):365-369. 被引量:87
  • 3龚燕冰,倪青,王永炎.中医证候研究的现代方法学述评(一)——中医证候数据挖掘技术[J].北京中医药大学学报,2006,29(12):797-801. 被引量:93
  • 4吴一龙,蒋国梁,廖美琳,周清华,陆舜,王绿化,张力,无.非小细胞肺癌孤立性转移处理共识[J].循证医学,2007,7(2):109-111. 被引量:21
  • 5吴秀艳,王天芳,赵燕,于春光,李志更,王庆国.数理分析方法在证候研究中的运用探析[J].江苏中医药,2007,39(7):53-55. 被引量:13
  • 6Travis WD, Asamura H, Bankier AA, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol, 2016. [Epub ahead of print].
  • 7Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC lung cancer staging proiect: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol, 2016, 11 (5): 651-665.
  • 8Detterbeck FC, Bolejack V, Arenberg DA, et al. The IASLC lung cancer staging project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol, 2016, 11 (5): 681-692.
  • 9Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac O ncol, 2016, 11(5): 639-650.
  • 10Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC lung cancer staging project: aackground data and proposals for the application of TNM staging rules to lung cancer presenting as multipIe nodules with ground glass or Iepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol, 2016, 11 (5): 666-680.

共引文献977

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部